MIAMI, Dec. 18, 2025 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (SABS) (Nasdaq: SABS), a clinical-stage biopharmaceutical company developing human anti-thymocyte immunoglobulin (hATG) for type 1 ...
Results demonstrated early signals of C-peptide preservationT1D key opinion leader, Michael J. Haller, MD, provided a recorded webinar reviewing ...
SAB-142 shows favorable safety and pharmacodynamic activity in Phase 1 trial, advancing to Phase 2b for type 1 diabetes. SAB BIO announced positive results from its Phase 1 trial of SAB-142, a novel ...
SAB BIO to Host Webinar Discussing Topline Results from Phase 1 Trial of SAB-142 for Type 1 Diabetes
SAB BIO will host a webinar on January 28, 2025, to discuss Phase 1 trial data for its T1D therapy, SAB-142. SAB BIO, a clinical-stage biopharmaceutical company, announced it will host a webinar on ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results